SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (14902)12/23/2004 10:46:08 AM
From: Arthur Radley  Read Replies (2) | Respond to of 52153
 
Any maven comments on INGN announcement today?
biz.yahoo.com



To: Biomaven who wrote (14902)12/23/2004 10:46:34 AM
From: bio_kruncher  Read Replies (2) | Respond to of 52153
 
I think the reaction in ADLR is overdone and have bought a bit. The NDA has already been submitted (last JUne) I don't think these results reduce chance of approval. In my opinion this study supports efficacy even though it did not reach required levels of significance. Seems they are quite unlucky in getting the endpoint but if you look at the total weight of evidence it still points toward being efficacious.

BK



To: Biomaven who wrote (14902)12/23/2004 8:53:05 PM
From: Steve168  Read Replies (2) | Respond to of 52153
 
PRCS below cash value, no debt, with FDA approved drug. It is undervalued based on my valuation method.

What do you think?

Any other biotechs that trades near cash value with no debt, and a FDA approved drug or a phase III trial?

Thanks,


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News